Tag Archives: healthcare

ZytoService reaches an agreement to acquire Profusio

ik-investment-partners

ZytoService, a leading compounder of pharmaceuticals for patient-individualised infusions, has reached an agreement with GHD GesundHeits GmbH to acquire Profusio, the second largest compounder of cytostatics in Germany. Financial terms of the transaction were not disclosed.

Founded in 2002, ZytoService is one of the largest industrially organised §13 AMG (“Arzneimittelgesetz”) certified compounders for patient-individualised infusions applied mainly in oncology treatment in Germany. The company is based in Hamburg, where it runs a state-of-the-art compounding facility.

Profusio, a subsidiary of GHD, is the second largest cytostatics compounder in Germany with state-of-the-art manufacturing facilities in Leipzig, Haan and Munich.

“Profusio’s facilities are very well-invested, and they share our high standards of quality, safety, and professional expertise. Together, we will work towards our vision to create an integrated healthcare provider in the German oncology market,” said Enno Scheel, Co-Founder of ZytoService.

“The acquisition of Profusio will strengthen ZytoService’s market position and national footprint, giving us even better opportunities to address the growing demands of the German healthcare market,” continued Thomas Boner, Co-Founder of ZytoService.

ZytoService is owned by the IK VIII Fund, which is advised by IK Investment Partners. Completion of the transaction is subject to customary legal and regulatory approvals.

For further questions:

ZytoService
Thomas Boner, Co-Founder and Co-CEO
Phone: +49 40 600 094 013

Enno Scheel, Co-Founder and Co-CEO
Phone: +49 40 600 094 01

About ZytoService
ZytoService was founded in Hamburg in 2002. ZytoService now employs more than 470 highly-qualified personnel who have undergone pharmaceutical training. All staff are specially trained in GMP-compliant production. With more than 40 licensed pharmacists, ZytoService has outstanding expertise in all areas of oncological pharmacy. For more information, visit www.zytoservice.de

 

Categories: News

Tags:

Atlas-backed I-O specialist Kyn comes out of stealth mode

Atlas Venture

The immuno-oncology sector has yet another player. Kyn Therapeutics just made its debut after almost two years of gestation at Atlas Venture with three immuno-metabolism platforms and $49 million in first-round funding.

Explaining the rationale behind the new company, CEO Mark Manfredi told us that “the dramatic successes of checkpoint inhibitors have made their deficiencies and opportunities for improvement a hot topic in the industry, and a major driver for investment.”

“We believe immuno-metabolism is the next big area for immuno-oncology therapeutics, as it has the potential to generate broad-spectrum immune stimulation either alone or in combination with checkpoint inhibitors.”

Kyn comes out of stealth mode with a pair of preclinical programs targeting the kynurenine pathway, which is implicated in a number of diseases including cancer, as well as ARY-007, a prostaglandin E2 (EP4) receptor antagonist licensed from Japan’s AskAt Inc. that will be developed alongside affiliate company Arrys Therapeutics.

ARY-007 has already been through human trials outside of cancer and will be Kyn’s first clinical candidate, starting phase 1b trials next year, said Manfredi. The company has a big-hitting rival for the program, however, as Bristol-Myers Squibb has just licensed an EP4 receptor antagonist from longtime immuno-oncology partner Ono Pharma for $40 million upfront.

“The literature has increasingly evidenced a broad-ranging immunosuppressive function for this receptor, through multiple cellular mechanisms,” said the CEO. “Once we understood this, it was an obvious choice to assess in the cancer immunotherapy setting.”

Kyn’s kynurenine pathway candidates are further back in development but have “substantial” preclinical data showing they can improve anti-tumor immune responses, according to Manfredi.

The first focuses on Kynase—an enzyme that degrades kynurenine directly and addresses both IDO (indoleamine 2,3-dioxygenase) and TDO (tryptophan 2,3-dioxygenase) immunosuppression pathways—and grew out of work the University of Texas at Austin.

There’s no shortage of other groups working on IDO—with BMS, Incyte and NewLink currently leading the charge—but fewer have focused on TDO. Kyn’s approach of targeting Kynase may lead to “efficacy in tumors that overexpress either IDO, TDO or both [and] therefore … could address a broader patient population than IDO inhibitors alone,” according to Manfredi. Added to that, its candidates seem to be much stronger at blocking kynurenine than IDO inhibitors in clinical trials.

The third pillar of Kyn’s portfolio is an in-house program geared towards developing aryl hydrocarbon receptor (AHR) antagonists that aim to block immunosuppression activated by various metabolites, including kynurenine.

The IDO/TDO and AHR programs are closely linked. In cancer cells, IDO and TDO stimulate the formation of kynurenine, which in turn activates AHR receptors and leads to an increase in immunosuppressive T cells in the tumor microenvironment. Moreover, AHR can also be activated by ligands other than kynurenine.

“In terms of clinical development, immunometabolism-based therapies are the next most advanced area within immuno-oncology,” he said, adding, “We think there is a lot of potential for our candidates in multiple solid tumors, but we’re not ready yet to talk specifics.”

“We also have a potential aid to efficiency in that the pathways we are exploring have several biomarkers—including the target metabolites themselves—that could lend themselves to patient enrichment approaches to study design.”

The $49 million in series A funding from Atlas and OrbiMed will be split two ways, with Arrys allocated $21 million for the EP4 project—which is subcontracted to Kyn—and the remaining $28 million going to the IDO/TDO and AHR programs, which should have lead development candidates selected in the next 12 to 18 months.

“We expect to add about 5 to 8 new employees internally over the next 12 months,” Manfredi told us. “Several of those employees will focus on candidate optimization and preclinical studies but we will also grow our internal clinical program management expertise.”

Categories: News

Tags:

HTL-Strefa strengthens Board of Directors with Rick Cook

eqt

HTL-Strefa is a fast-growing global med-tech company and pioneer in the medical sharps’ industry. The company is going through an exciting phase – transforming its commercial profile and execution capabilities, which has led to higher demand from customers. In order to fulfill the increased demand and to support the implementation of new investments in production, Rick Cook, former Global Head of Operations at Becton Dickinson, will join HTL-Strefa’s Board of Directors.

EQT V portfolio company HTL-Strefa is a global leading provider of proprietary capillary blood sampling and hypodermic injection devices. Global demographic megatrends, such as a growing number of insulin users and increasing need for safe point-of-care blood tests, underpin a solid underlying market growth for years to come. During EQT’s ownership, HTL-Strefa has embarked on a transformation journey from being a local manufacturer to a fully-fledged international medical device player.

Since the appointment of CEO Mikkel Danvold in January 2017 and the strengthening of HTL-Strefa’s management team, the top-line growth and earnings trajectory have been reinvigorated. The improved performance is the result of changing the commercial approach ensuring that customers and end-users are at the center of all decision-making. This approach has already led to a large number of new customers, an ongoing repositioning in the value chain, as well as implementation of multiple initiatives to ensure state-of-the-art commercial excellence and product innovation.

To meet the increased demand from both existing and new customers, HTL-Strefa is scaling up its organization and production capacity significantly. To support management in the implementation of the new expansion projects, Rick Cook will join HTL-Strefa’s Board of Directors. Rick has more than 30 years of experience in manufacturing and operations for Intravenous solutions and medical devices at all levels, from floor supervision to global operations leadership.

“As former Global Head of Operations at Becton Dickinson, Rick has a long track-record from leading large-scale projects within production and operations in the med-tech industry. Rick brings impressive experience which will be highly valuable to HTL-Strefa’s ongoing transformation. Supporting Mikkel and his team in implementing excellence in quality, service and cost from operations will bring competitive differentiation and enhanced value for customers”, says Gerard Van Odijk, Chairman of the Board of Directors at HTL-Strefa.

“I am honored to be asked to serve on HTL-Strefa’s Board of Directors. I look forward to helping Mikkel and the Operations team build upon the existing strong foundation and create a manufacturing culture and capability that will serve global customers of HTL with excellence in the exciting years ahead”, says Rick Cook, new Board Member of HTL-Strefa.

With the new commercial agenda being implemented, HTL-Strefa is uniquely positioned to further accelerate execution on the many top-line growth initiatives. The plan includes among other things a rapid channel expansion and launch of numerous new innovative products with distinct end-user benefits.

During EQT’s ownership, HTL-Strefa’s revenues have been growing at high single-digit rates and EBITDA margins have increased. With accelerated investments in product innovation and the implementation of an enhanced commercial strategy, growth has improved further to solid double-digit rates and are expected to continue to rise.

 

Categories: People

Tags:

Nordic Capital invests in German healthcare operator Alloheim

Nordic Capital

Nordic Capital Fund VIII today announces its acquisition of Alloheim, the second largest private German care home operator.

Alloheim offers nationwide care services for different age groups in stationary care homes, at assisted living locations and via ambulatory services. Alloheim which was a pioneer in the German market having opened its first location in 1973, has grown to employ c. 14,500 medical professionals and staff and is home to up to 20,000 residents.

Nordic Capital is an established healthcare investor with a track record of building high quality, sustainable businesses. Nordic Capital intends to support Alloheim management’s strategy to continue to deliver high quality services and care to its residents, and to invest in further expanding the facilities and services offered by Alloheim.

The transaction is subject to customary antitrust and regulatory approvals.

 

 

Media contacts:

Katarina Janerud, Communications manager
Advisor to the Nordic Capital Funds
Tel: +46 8 440 50 50
e-mail: katarina.janerud@nordiccapital.com

 Nordic Capital invests in German healthcare operator Alloheim Image

About Alloheim

Alloheim is the second largest private and one of the fastest growing German nursing home operators with more than 170 stationary nursing care homes (incl. 10 new-builds under construction), 52 facilities for assisted living and 17 ambulatory care services. The group provides in total c. 20,000 beds of which 18,000 are stationary care beds and c. 2,000 apartments for assisted living. Amongst the stationary care services, the group offers a variety of specialized care including advanced dementia, youth & psychiatric care, adiposity and artificial respiration. Alloheim currently employs around 14,500 employees. Headquarter is in Duesseldorf, Germany. For further information about Alloheim please visit www.alloheim.de

About Nordic Capital

Nordic Capital is a leading private equity investor in the Nordic region with a resolute commitment to creating stronger, sustainable businesses through operational improvement and transformative growth. Nordic Capital focuses on selected regions and sectors where it has deep experience and a proven track record. Core sectors are Healthcare, Technology & Payments, Financial Services, Industrial Goods & Services and Consumer & Retail, and key regions are the Nordics, Northern Europe, and globally for Healthcare. Since inception in 1989, Nordic Capital has invested EUR 11 billion through eight funds. The Nordic Capital Funds are based in Jersey and are advised by advisory entities, which are based in Sweden, Denmark, Finland, Norway, Germany and the UK. For further information about Nordic Capital please see www.nordiccapital.com

 

Categories: News

Tags:

Cirtec expands internationally through acquisition of Vascotube

3I

3i-backed Cirtec Medical (“Cirtec”) has acquired Vascotube Gmbh (“Vascotube”), a market leading manufacturer of precision-engineered nitinol tubing. Vascotube aligns with Cirtec’s strategy to both further vertically integrate and expand its capabilities within minimally invasive interventional therapies. The combined business will have enhanced capabilities across components and fully assembled devices and a broader geographic footprint, all of which enable Cirtec to better serve its customers. Vascotube’s management team will remain in their current leadership roles with the company.

Vascotube, headquartered in Birkenfield, Germany and founded in 2004, offers nitinol tubing used in minimally invasive implantable medical devices such as replacement heart valves, peripheral vascular and neurovascular stents. Nitinol tubing is made from a nickel and titanium alloy and is a valued and differentiated product due to its unique shape memory capabilities and elasticity properties. These characteristics are critical for minimally invasive implantable medical devices where scaffold-like structures are compressed, inserted intravenously into the body and then expanded to pre-set shapes. The business’ proprietary manufacturing process and strict focus on quality is a key differentiator, and has made it a leading provider in its target markets and with its customers.

Brian Highley, CEO, Cirtec commented:
“Vascotube complements our capabilities to include precision-engineered nitinol tube drawing technology. It also expands our geographic footprint into Europe and further diversifies Cirtec’s exposure to a broad range of highly attractive and rapidly growing therapeutic categories with industry leading customers and products. We are thrilled to be adding a new set of highly differentiated capabilities to offer our customers.”

Uwe Seiler, Managing Director, Vascotube added:
“We are happy to have found a strong partner in Cirtec that can help us grow our sales footprint and better support our customers. The Cirtec and Vascotube offerings are highly complementary and focus on quality, high-end technical products and solutions that are customized to serve the critical needs of our customers. We are excited about the next chapter of growth that can be achieved by partnering with Cirtec.”

Richard Relyea, Partner at 3i, US noted:
“We are delighted to continue our support of Cirtec through this transformational combination with Vascotube. Together, they will be one of the most differentiated medical device outsourced manufacturers in the market, with exposure to several of the most attractive growth categories in the industry and a strength in design, development and manufacturing of challenging and technically complex devices and components.”

In July 2017, 3i invested in Cirtec, a leading provider of outsourced medical device design, engineering and manufacturing. 3i is supporting Cirtec to execute its robust organic growth strategy and expand its offerings through targeted acquisitions within the highly fragmented MDO market.

-Ends-

For further information, contact:

3i Group plc
Silvia Santoro
Investor enquiries
Tel: +44 20 7975 3258
Email: silvia.santoro@3i.com

Kathryn van der Kroft
Media enquiries
Tel: +44 20 7975 3021
Email: kathryn.vanderkroft@3i.com

Notes to editors:

About Cirtec
For over 25 years, Cirtec has been providing design, development, manufacturing and product transfer services for the medical device industry. With facilities in Los Gatos, CA, Enfield, CT and Brooklyn Park, MN, the company specialises in outsourced solutions for active implantable devices in the areas of neuromodulation, drug delivery, cardiac rhythm management, ventricular assist, and minimally invasive devices. Companies rely on Cirtec’s expertise throughout the entire development cycle to bring life-enhancing therapies to market. For more information on Cirtec, please visit http://cirtecmed.com/

About Vascotube
Vascotube is based in Baden-Wuerttemberg, Germany, situated in the heart of Germany’s automotive, mechanical and medical industries. Vascotube continues the region’s historical tradition for fine precision craftsmanship and the quality reputation of “Made in Germany” products in its approach to producing nitinol and other metal tubes. Vascotube concentrates on tubing that is used in medical devices and serves customers globally. For more information on Vascotube, please visit http://www.vascotube.com/en/

About 3i Group
3i is an investment company with two complementary businesses, Private Equity and Infrastructure, specialising in core investment markets in Northern Europe and North America.

3i’s Private Equity team provides investment solutions for growing companies, backing entrepreneurs and management teams of mid-market companies. We back international growth plans, providing access to our network and expertise to accelerate the growth of companies across the consumer, industrials and business and technology services industries.

For further information, please visit: www.3i.com

Categories: News

Tags:

Eurazeo Patrimoine enters into exclusive discussions with Bridgepoint to Acquire C2S Group

Eurazeo

Eurazeo Patrimoine has entered into exclusive discussions with Bridgepoint to acquire the C2S private clinic group.

C2S Group is the eighth largest private clinic operator in France and a regional leader in Auvergne Rhône-Alpes and Burgundy Franche-Comté. It operates 11 clinics, primarily specializing in general medicine, surgery and obstetrics. It also owns the buildings for 7 of its clinics. The group has 500 medical practitioners and nearly 1,800 employees and reported revenue of €158 million in 2016

About Eurazeo

With a diversified portfolio of approximately ~€7 billion in assets under management, of which €1 billion is from third parties, Eurazeo is a leading global investment company with offices in Paris and Luxembourg, New York, Shanghai and Sao Paolo. Its purpose and mission is to identify, accelerate and enhance the transformation potential of the companies in which it invests. The firm covers most private equity segments through its five business divisions–Eurazeo Capital, Eurazeo Croissance, Eurazeo PME, Eurazeo Patrimoine and Eurazeo Brands. Its solid institutional and family shareholder base, robust financial structure free of structural debt, and flexible investment horizon enable Eurazeo to support its companies over the long term. As a global long-term shareholder, the firm offers deep sector expertise, a gateway to global markets, and a stable foothold for transformational growth to the companies it supports.

Eurazeo is listed on Euronext Paris.

ISIN: FR0000121121

Bloomberg: RF FP

Reuters: EURA.PA

Categories: News

Tags:

Cirtec expands internationally through acquisition of Vascotube

3I

3i-backed Cirtec Medical (“Cirtec”) has acquired Vascotube Gmbh (“Vascotube”), a market leading manufacturer of precision-engineered nitinol tubing. Vascotube aligns with Cirtec’s strategy to both further vertically integrate and expand its capabilities within minimally invasive interventional therapies. The combined business will have enhanced capabilities across components and fully assembled devices and a broader geographic footprint, all of which enable Cirtec to better serve its customers. Vascotube’s management team will remain in their current leadership roles with the company.

Vascotube, headquartered in Birkenfield, Germany and founded in 2004, offers nitinol tubing used in minimally invasive implantable medical devices such as replacement heart valves, peripheral vascular and neurovascular stents. Nitinol tubing is made from a nickel and titanium alloy and is a valued and differentiated product due to its unique shape memory capabilities and elasticity properties. These characteristics are critical for minimally invasive implantable medical devices where scaffold-like structures are compressed, inserted intravenously into the body and then expanded to pre-set shapes. The business’ proprietary manufacturing process and strict focus on quality is a key differentiator, and has made it a leading provider in its target markets and with its customers.

Brian Highley, CEO, Cirtec commented:
“Vascotube complements our capabilities to include precision-engineered nitinol tube drawing technology. It also expands our geographic footprint into Europe and further diversifies Cirtec’s exposure to a broad range of highly attractive and rapidly growing therapeutic categories with industry leading customers and products. We are thrilled to be adding a new set of highly differentiated capabilities to offer our customers.”

Uwe Seiler, Managing Director, Vascotube added:
“We are happy to have found a strong partner in Cirtec that can help us grow our sales footprint and better support our customers. The Cirtec and Vascotube offerings are highly complementary and focus on quality, high-end technical products and solutions that are customized to serve the critical needs of our customers. We are excited about the next chapter of growth that can be achieved by partnering with Cirtec.”

Richard Relyea, Partner at 3i, US noted:
“We are delighted to continue our support of Cirtec through this transformational combination with Vascotube. Together, they will be one of the most differentiated medical device outsourced manufacturers in the market, with exposure to several of the most attractive growth categories in the industry and a strength in design, development and manufacturing of challenging and technically complex devices and components.”

In July 2017, 3i invested in Cirtec, a leading provider of outsourced medical device design, engineering and manufacturing. 3i is supporting Cirtec to execute its robust organic growth strategy and expand its offerings through targeted acquisitions within the highly fragmented MDO market.

-Ends-

For further information, contact:

3i Group plc
Silvia Santoro
Investor enquiries
Tel: +44 20 7975 3258
Email: silvia.santoro@3i.com

Kathryn van der Kroft
Media enquiries
Tel: +44 20 7975 3021
Email: kathryn.vanderkroft@3i.com

Notes to editors:

About Cirtec
For over 25 years, Cirtec has been providing design, development, manufacturing and product transfer services for the medical device industry. With facilities in Los Gatos, CA, Enfield, CT and Brooklyn Park, MN, the company specialises in outsourced solutions for active implantable devices in the areas of neuromodulation, drug delivery, cardiac rhythm management, ventricular assist, and minimally invasive devices. Companies rely on Cirtec’s expertise throughout the entire development cycle to bring life-enhancing therapies to market. For more information on Cirtec, please visit http://cirtecmed.com/

About Vascotube
Vascotube is based in Baden-Wuerttemberg, Germany, situated in the heart of Germany’s automotive, mechanical and medical industries. Vascotube continues the region’s historical tradition for fine precision craftsmanship and the quality reputation of “Made in Germany” products in its approach to producing nitinol and other metal tubes. Vascotube concentrates on tubing that is used in medical devices and serves customers globally. For more information on Vascotube, please visit http://www.vascotube.com/en/

About 3i Group
3i is an investment company with two complementary businesses, Private Equity and Infrastructure, specialising in core investment markets in Northern Europe and North America.

3i’s Private Equity team provides investment solutions for growing companies, backing entrepreneurs and management teams of mid-market companies. We back international growth plans, providing access to our network and expertise to accelerate the growth of companies across the consumer, industrials and business and technology services industries.

For further information, please visit: www.3i.com

Categories: News

Tags:

Mytonomy Announces Series A Financing Headlined by an Investment from Philips

Philips Ventures

Bethesda, Maryland –November 29, 2017 – Mytonomy, a leader in provider driven patient experience solutions to improve patient outcomes, announced it is closing a $7M Series-A funding round, including an investment from Philips, a global leader in health technology.

“Philips brings an extensive track record in consumer health and professional healthcare in key areas that align with Mytonomy’s growth, such as cardiology, oncology, imaging, mother/child care and population health. Philips is a value-add investor as we scale our Patient Experience Cloud business. We are thrilled to have members of the Philips Health Technology Ventures team join our board as they bring decades of healthcare industry and software execution expertise,” said Anjali Kataria, CEO of Mytonomy.

“Mytonomy’s software platform drives multiple benefits for many stakeholders in the provider environment, simultaneously; we drive longitudinal patient activation, improve patient, family and staff satisfaction, decrease labor costs, and increase top-line growth by delivering a significantly better, data-driven, personalized patient experience across the entire care continuum,” said Kataria.

“The results that Mytonomy and its founders have achieved in recent years are very impressive,” said Rich Wilmot, head of Philips Health Technology Ventures. “Their innovative product has strong traction in the market as hospitals achieve very high patient satisfaction from patients who use Mytonomy’s cloud-based patient education system. Moreover, Philips and Mytonomy share a joint vision of marrying unique data sets such as patient-reported outcomes and clinical metrics to drive better clinical outcomes, while enhancing the patient experience, and driving down inefficiencies and cost. We look forward to teaming up with Mytonomy to help grow the business, and ultimately forge a productive partnership path for the two companies.”

Other notable investors include MedStar Health and Super Angels such as George John, co-founder of Rocket Fuel and an AI thought leader, and Gokul Rajaram, Head of Product for Square and a former Facebook and Google executive.

Mytonomy seamlessly spans pre-procedure, pre-arrival, in-patient, discharge, at home, and ambulatory care with a consumer like experience that is both high-tech and high-touch increasing labor efficiency of staff. “Nurses call Mytonomy their virtual assistant,” said Kataria.

“Like popular consumer video streaming services, Mytonomy delivers personalized content directly to patients on any device throughout their care journey,” said Vinay Bhargava, Mytonomy’s Co-founder and President. “Bringing user-centric design principles to healthcare has led to very high patient usage across all major demographics and is delivering a fantastic, tailored patient experience for each patient,” he said.

The patient experience is of paramount importance to the healthcare industry.  Gartner’s 2017 report “The Future of Experience in Healthcare Demands a Consumer-Aligned Collaborative Ecosystem”*, includes the following observations:

  • Sixty-one percent of U.S. integrated delivery systems (IDSs) now have a senior executive specifically charged with accountability for the patient experience.
  • The experiences that consumers have in healthcare — positive or negative — influence their future decisions when navigating the healthcare system and their personal health behaviors. These decisions are powerful determinants of health outcomes and medical costs.

 

*Gartner, “The Future of Experience in Healthcare Demands a Consumer-Aligned Collaborative Ecosystem,” Jeff Cribbs, Mark E. Gilbert, 28 April 2017.

About Mytonomy

Mytonomy is the leader in Patient Experience Cloud Software for hospitals and providers. Leveraging behavior science, Mytonomy offers a data driven personalized patient education, engagement and experience software platform resulting in unprecedented cost savings and improvements in patient outcomes. Our cloud software combined with modern microlearning video education enables seamless access across the care continuum:  pre-procedure, pre-arrival, in-patient, discharge, at home, rehabilitation and ambulatory care with a consumer like experience, that is both high-tech and high-touch.  Mytonomy’s founders are former executives from Google, Oracle, and the FDA.  The company is headquartered in Bethesda, MD. For more information, visit www.mytonomy.com.

Categories: News

Tags:

Medical Artificial Intelligence company Quantib receives capital injection of EUR 4.5 million

Faster and more objective diagnoses by automatic interpretation of MRI and CT scan data

Chicago, 27 November 2017 – At the world’s largest radiology conference (RSNA), medical Artificial Intelligence (AI) company Quantib announced today that it secured €4.5mln ($ 5.4mln) of fresh funding in a round that was led by Holland Venture and InnovationQuarter. Quantib develops Machine Learning (ML) applications for medical imaging analyses, allowing physicians and researchers to make more efficient and more accurate diagnoses. The investment supports Quantib with her international scale-up ambitions.

Founded in 2012 and headquartered in Rotterdam, The Netherlands, Quantib is one of the most renowned Dutch players in the field of medical AI applications. Quantib utilizes ML software for the segmentation, classification and quantification of medical images, improving diagnostic quality and allowing for a more efficient workflow of physicians and researchers. Quantib is a spin-off of the Erasmus MC, developing her products in close collaboration with the internationally recognized Biomedical Imaging Group Rotterdam (BIGR) under supervision of Prof. dr. Wiro Niessen. Moreover, Quantib has strong partnerships with industry players (GE Healthcare, Philips and Intrasense) for research, development and the distribution of her products. Recently, Quantib received media coverage as winner of The Dutch Data Science prize . Quantib’s first products received FDA approval and CE marking in 2016 and focus on the detection and tracking of neurological disorders such as Parkinson, Multiple Sclerosis and Alzheimer’s disease.

The investment allows Quantib to bring new ML applications to the market with regards to stroke, lung disorders, oncology and bone structures. Quantib will also establish new partnerships with leading international academic hospitals.

In conjunction with the investment, the management team has been reinforced with Arthur Post Uiterweer (former Philips and Boston Consulting Group) and Jorrit Glastra (former Shell). The supervisory board will consist of Prof. dr. Gabriel Krestin, Harm-Jan Wessels and health entrepreneur Jaap Maljers.

Rudolf Scholte, CEO of Quantib: “Our software supports radiologists and neurologists with their objective assessment of MRI- and CT scans. Our deep learning algorithms can support better diagnoses, and a better assessment of treatments’ effectiveness. Up until now, our main focus was on brain disorders. This investment allows us to develop new products and to extend our team.”

“Quantib’s applications help standardise and speed up image analysis and allows for the detection of subtle changes over time. It increases the objectivity of the diagnostic process and therefore delivers an improved diagnosis combined with more efficient processes, positively impacting a large group of patients. We see large international growth opportunities for the company and we are proud to be a part of this development.” says Ewout Prins, Managing Partner Holland Venture.

Francis Quint, Head InnovationQuarter Capital: “Quantib facilitates faster, better and more efficient diagnoses, a fantastic result from the close collaboration with Erasmus MC. We are happy to support this Rotterdam-based company with their ambition to extend the range of their current technology to other applications.”

Categories: News

Tags:

Roche Acquires Lab Data Analytics Platform Viewics

Canvas Ventures

Roche Acquires Lab Data Analytics Platform Viewics

Roche, a pharmaceuticals and diagnostics focused on advancing science has announced an agreement to acquire Viewics, Inc., a laboratory business analytics platform. Under the terms of the agreement, Roche is acquiring all shares of the company. Financial details of the acquisition were not disclosed.

As part of the acquisition, Viewics, Inc. will become an integral part of Roche and add further digital capabilities on top of Roche Diagnostics’ Integrated Core Lab offering to make faster data-driven informed decisions on their operations and processes.  The cloud-based solution is secure, infrastructure-agnostic, interactive, and accessible from multiple devices (e.g. smart phones, tablets, desktop computers).

Founded in 2010 in Sunnyvale, CA, the Viewics solution allows for efficient integration of big data from a variety of IT systems in the laboratory and beyond, pioneering a new way in extracting, cleansing, transforming and augmenting data. The HIPAA-compliant solution puts the transformational power of analytics into the hands of healthcare professionals in laboratory, financial, executive, and IT roles.

The solution enables organizations to leverage insights out-of-the-box, combined with the flexibility of further customising the solution to meet the needs of their unique situations, truly interact with their data and make decisions based on accurate information to deliver significant impact.

Categories: News

Tags: